The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
Abstract
Strong evidence has been presented linking chronic inflammation to the onset and pathogenesis of cancer. The multifunctional pro‐inflammatory protein macrophage migration inhibitory factor (MIF) occupies a central role in the inflammatory pathway and has been implicated in the tumorigenesis, angiogenesis, and metastasis of many cancer phenotypes. This review highlights the current state of the art, which presents MIF, and the second member of the MIF structural superfamily, d‐DT (MIF2), as significant mediators in the inflammatory–cancer axis. Although the mechanism by which MIF asserts its biological activity has yet to be fully understood, it has become clear in recent years that for certain phenotypes of cancer, MIF represents a valid therapeutic target. Current research efforts have focused on small molecule approaches that target MIF's unique tautomerase active site and neutralization of MIF with anti‐MIF antibodies. These approaches have yielded promising results in a number of preclinical murine cancer models and have helped to increase our understanding of MIF biological activity. More recently, MIF's involvement in a number of key protein–protein interactions, such as with CD74 and HSP90, has been highlighted and provides a novel platform for the development of anti‐MIF chemotherapeutic strategies in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Lüscher, B., & Bernhagen, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210318 · Cited by 385
Cited by
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Sumaiya, K., Langford, D., Natarajaseenivasan, K., & Shanmughapriya, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108024 · Cited by 299
Wang, L., Li, S., Luo, H., Lu, Q., & Yu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02477-0 · Cited by 271
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Metadata
- Authors
- O'Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2016-01-18
- Volume
- 36
- Issue
- 3
- Pages
- 440-460
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2310474609
- Cited by
- 180
- References
- 4
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. https://app.cochat.ai/papers/10.1002/med.21385
- The paper
- O'Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C. (2016). Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. Medicinal Research Reviews. https://doi.org/10.1002/med.21385
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.